North America Regenerative Medicine Market Size & Outlook
North America regenerative medicine market, 2018-2030 (US$M)
Related Markets
North America regenerative medicine market highlights
- The North America regenerative medicine market generated a revenue of USD 17,776.4 million in 2023.
- The market is expected to grow at a CAGR of 16.5% from 2024 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2023.
- Banks is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 17,776.4 million |
| Market revenue in 2030 | USD 51,781.7 million |
| Growth rate | 16.5% (CAGR from 2023 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Banks |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Therapeutics, Tools, Banks, Services |
| Key market players worldwide | AstraZeneca PLC, Roche Holding AG, Integra Lifesciences Holdings Corp, Astellas Pharma Inc, Cook Group, Bayer AG, Pfizer Inc, Merck KGaA, Abbott Laboratories, Vericel Corp, Novartis AG ADR, GlaxoSmithKline |
Other key industry trends
- In terms of revenue, North America region accounted for 58.4% of the global regenerative medicine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 27,062.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Regenerative Medicine Market Scope
Regenerative Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America regenerative medicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regenerative medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 75.87% in 2023. Horizon Databook has segmented the North America regenerative medicine market based on therapeutics, tools, banks, services covering the revenue growth of each sub-segment from 2018 to 2030.
North America held a significant share of the global regenerative medicine market. Its growth can be attributed to factors such as increasing investments in the regenerative medicine domain and a growing focus on launching new centers for regenerative medicine. Moreover, the developments in gene therapy, cell therapy, and tissue engineered products in the region are expected to fuel the competition. For instance, in June 2022, Astellas Pharma, Inc. opened a new facility in North Carolina for developing gene therapy.
Moreover, in July 2023, Pfizer invested USD 25 million in Caribou Biosciences, a player operating in the North American market. The company was expected to use this money for its allogeneic CAR T-cell therapy for patients with multiple myeloma. Thus, growing investment by key players to expand their production capacity and develop cell & gene therapies is anticipated to boost the market growth in the region further.
Reasons to subscribe to North America regenerative medicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America regenerative medicine market databook
-
Our clientele includes a mix of regenerative medicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America regenerative medicine market , including forecasts for subscribers. This continent databook contains high-level insights into North America regenerative medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America regenerative medicine market size, by country, 2018-2030 (US$M)
North America Regenerative Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
